Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice.
BACKGROUND
Fat inflammation may play an important role in comorbidities associated with obesity such as atherosclerosis.


RESULTS
To first establish feasibility of fat transplantation, epididymal fat pads were harvested from wild-type C57BL/6J mice and transplanted into leptin-deficient (Lep(ob/ob)) mice. Fat transplantation produced physiological leptin levels and prevented obesity and infertility in Lep(ob/ob) mice. However, the transplanted fat depots were associated with chronically increased macrophage infiltration with characteristics identical to those observed in fat harvested from obese animals. The inflammation in transplanted adipose depots was regulated by the same factors that have been implicated in endogenous fat inflammation such as monocyte chemoattractant protein-1. To determine whether this inflamed adipose depot could affect vascular disease in mice, epididymal fat depots were transplanted into atherosclerosis-prone apolipoprotein E-deficient ApoE(-/-) mice. Plasma from ApoE(-/-) mice receiving fat transplants contained increased leptin, resistin, and monocyte chemoattractant protein-1 compared with plasma from sham-operated ApoE(-/-) mice. Furthermore, mice transplanted with visceral fat developed significantly more atherosclerosis compared with sham-operated animals, whereas transplants with subcutaneous fat did not affect atherosclerosis despite a similar degree of fat inflammation. Treatment of transplanted ApoE(-/-) mice with pioglitazone decreased macrophage content of the transplanted visceral fat pad and reduced plasma monocyte chemoattractant protein-1. Importantly, pioglitazone also reduced atherosclerosis triggered by inflammatory visceral fat but had no protective effect on atherosclerosis in the absence of the visceral fat transplantation.


CONCLUSIONS
Our results indicate that visceral adipose-related inflammation accelerates atherosclerosis in mice. Drugs such as thiazolidinediones might be a useful strategy to specifically attenuate the vascular disease induced by visceral inflammatory fat.
Ohman
Miina K
MK
University of Michigan, Department of Internal Medicine, Division of Cardiology, Ann Arbor 48109-0644, USA.
Shen
Yuechun
Y
Obimba
Chinyere I
CI
Wright
Andrew P
AP
Warnock
Mark
M
Lawrence
Daniel A
DA
Eitzman
Daniel T
DT
D052242:Adiponectin / Q000097:blood; D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency*; D050197:Atherosclerosis / Q000188:drug therapy / Q000209:etiology*; D007249:Inflammation / Q000150:complications / Q000473:pathology / Q000503:physiopathology*; D050152:Intra-Abdominal Fat / Q000473:pathology / Q000502:physiology* / Q000637:transplantation; D020738:Leptin / Q000172:deficiency; D008264:Macrophages / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use*
D052242:Adiponectin; D001057:Apolipoproteins E; D020738:Leptin; D045162:Thiazolidinediones; D000077205:Pioglitazone